{
    "root": "2f9b625f-3835-4481-e063-6394a90a4bf3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Deferasirox",
    "value": "20250305",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "DEFERASIROX",
            "code": "V8G4MOF2V9"
        }
    ],
    "indications": "deferasirox iron chelator indicated treatment chronic iron overload due blood transfusions patients 2 years age older . ( 1.1 ) deferasirox indicated treatment chronic iron overload patients 10 years age older non‑transfusion-dependent thalassemia ( ntdt ) syndromes , liver iron ( fe ) concentration ( lic ) least 5 mg fe per gram dry weight serum ferritin greater 300 mcg/l . ( 1.2 ) limitations : safety efficacy deferasirox administered iron chelation therapy established . ( 1.3 )",
    "contraindications": "transfusional iron overload : initial dose patients estimated glomerular filtration rate ( egfr ) greater 60 ml/min/1.73 2 20 mg per kg body weight daily , oral suspension . calculate dose nearest whole tablet . ( 2.1 ) ntdt syndromes : initial dose patients egfr greater 60 ml/min/1.73 2 10 mg per kg body weight daily , oral suspension . calculate dose nearest whole tablet . ( 2.2 )",
    "warningsAndPrecautions": "deferasirox provided 125 mg , 250 mg , 500 mg tablets oral suspension . 125 mg white off-white , round , flat beveled edged tablet debossed “ d1 ” one side . bottles 30 tablets child-resistant closure……………………………ndc 69452-159-13 250 mg white off-white , round , flat beveled edged tablet debossed “ d2 ” one side . bottles 30 tablets child-resistant closure ……………………………ndc 69452-160-13 500 mg white off-white , round , flat beveled edged tablet debossed “ d3 ” one side . bottles 30 tablets child-resistant closure ……………………………ndc 69452-161-13 store deferasirox tablets oral suspension 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "deferasirox contraindicated patients : estimated gfr less 40 ml/min/1.73 2 [ ( 2.5 ) , ( 5.1 ) ] ; poor performance status ; [ ( 5.1 , 5.3 ) ] high-risk myelodysplastic syndromes ; ( patient population studied expected benefit chelation therapy ) advanced malignancies . [ ( 5.1 , 5.3 ) ] platelet counts less 50 x 10 9/l [ ( 5.3 , 5.4 ) ] known hypersensitivity deferasirox component deferasirox tablets oral suspension [ ( 5.7 ) , ( 6.2 ) ] .",
    "indications_original": "Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non‑transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. ( 1.3 )",
    "contraindications_original": "Transfusional Iron Overload: Initial dose for patients with estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m 2 is 20 mg per kg body weight once daily, as oral suspension. Calculate dose to the nearest whole tablet. ( 2.1 ) NTDT Syndromes: Initial dose for patients with eGFR greater than 60 mL/min/1.73 m 2 is 10 mg per kg body weight once daily, as oral suspension. Calculate dose to the nearest whole tablet. ( 2.2 )",
    "warningsAndPrecautions_original": "Deferasirox is provided as 125 mg, 250 mg, and 500 mg tablets for oral suspension.\n                  \n                     125 mg\n                  \n                  White to off-white, round, flat beveled edged tablet debossed with “D1” on one side.\n                  Bottles of 30 tablets with child-resistant closure……………………………NDC 69452-159-13\n                  \n                     250 mg\n                  \n                  White to off-white, round, flat beveled edged tablet debossed with “D2” on one side.\n                  Bottles of 30 tablets with child-resistant closure ……………………………NDC 69452-160-13\n                  \n                     500 mg\n                  \n                  White to off-white, round, flat beveled edged tablet debossed with “D3” on one side.\n                  Bottles of 30 tablets with child-resistant closure ……………………………NDC 69452-161-13\n                  Store deferasirox tablets for oral suspension at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Deferasirox is contraindicated in patients with:\n                  \n                     Estimated GFR less than 40 mL/min/1.73 m\n  \n   2 \n                        [see Dosage and Administration (\n   \n    2.5)\n  \n   ,\n  \n   Warnings and Precautions (\n   \n    5.1)]\n  \n   ;\n \n  \n                     Poor performance status; \n  \n   [see Warnings and Precautions (\n   \n    5.1, \n   \n    5.3)]\n  \n   \n                     \n                     High-risk myelodysplastic syndromes; \n  \n   (this patient population was not studied and is not expected to benefit from chelation therapy)\n                     \n                     Advanced malignancies.\n  \n   [see Warnings and Precautions (\n   \n    5.1,  \n   \n    5.3)]\n  \n   \n                     \n                     Platelet counts less than 50 x 10\n  \n   9/L \n  \n   [see Warnings and Precautions (\n   \n    5.3, \n   \n    5.4)]\n  \n   \n                     \n                     Known hypersensitivity to deferasirox or any component of deferasirox tablets for oral suspension \n  \n   [see Warnings and Precautions (\n   \n    5.7), Adverse Reactions (\n   \n    6.2)]\n  \n   ."
}